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A B S T R A C T
Ubiquitous Chromatin-opening Elements (UCOEs) are deﬁned by their ability to consistently confer stable, site of
integration-independent transgene expression that is proportional to copy number, including from within
regions of heterochromatin such as centromeres. UCOEs structurally consist of methylation-free CpG islands
encompassing single or dual divergently-transcribed housekeeping gene promoters. Since their discovery in
1999, UCOEs and their sub-fragments have found applications in areas of biotechnology requiring stable,
reproducible, and high levels of gene expression. This review recounts the discovery of UCOEs and examines
their current and future applications in protein therapeutic biomanufacturing and gene therapy.
1. Introduction
The random integration of a transgene into a heterochromatic
chromatin environment and the methylation of promoter DNA are
major mechanisms that are antagonistic to gene expression, resulting in
a variegated pattern of gene expression or silencing (Pikaart et al.,
1998; Yang et al., 2010). Because stable and high level transgene
expression are essential for the eﬃcient and rapid production of clonal
cell lines in biomanufacturing as well as for the lifelong expression of a
transgene at a therapeutic level in gene therapy, there is a fundamental
requirement for genetic regulatory elements, which can prevent gene
silencing and maintain high levels of expression for long periods of
time.
Genetic regulatory elements that confer a transcriptionally permis-
sive state can be broadly dichotomised into those that actively function
through dominant chromatin remodelling mechanisms and those that
function as border or boundary elements to restrict the spread of
heterochromatin marks into regions of euchromatin. The latter include
insulators, scaﬀold/matrix attachment regions (S/MARs), and stabilis-
ing anti-repressor (STAR) elements, whilst the former comprise locus
control regions (LCRs) and ubiquitous chromatin opening elements
(UCOEs). LCRs and UCOEs are deﬁned by their ability to consistently
confer site of integration-independent stable transgene expression that
is proportional to transgene copy number, even when integrated into
heterochromatin (Antoniou et al., 2003; Li et al., 2002). LCRs are
tissue-speciﬁc regulatory elements that consist of multiple subcompo-
nents characterised by DNase I hypersensitivity and a high density of
transcription factor binding sites (Kim and Dean, 2012; Li et al., 2002;
Tam et al., 2006). In contrast, UCOEs function ubiquitously and neither
consist of multiple DNase I hypersensitive sites that are characteristic of
LCRs, nor are they required to ﬂank a transgene at both 5′ and 3′ ends in
order to exert their function as in the case of insulators and S/MARs
(Antoniou et al., 2003; Williams et al., 2005). Thus, structurally and
functionally UCOEs represent a distinct class of genetic regulatory
element.
UCOEs have found widespread usage in protein therapeutic bioma-
nufacturing applications as a means to manage costs and resources as
well as to reliably expedite the generation of highly expressing
recombinant cell clones. Similarly, UCOEs show great promise in the
ﬁeld of gene therapy by providing stable ubiquitous or tissue-speciﬁc
expression in somatic tissues as well as in adult, embryonic, and
induced pluripotent stem cells and their diﬀerentiated progeny. This
review recounts the discovery of UCOEs, and discusses their application
in biomanufacturing and gene therapy.
2. Discovery of ubiquitous chromatin-opening elements
The ﬁrst genomic fragment found to possess a ubiquitous chroma-
tin-opening function and protect against the epigenetic silencing of
transgenes was derived from the TATA-binding protein (TBP) locus, a
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region encompassing the TBP and proteosomal subunit C5-encoding
(PSMB1) housekeeping genes (Fig. 1A) (Harland et al., 2002). TBP and
PSMB1 are closely linked (within 1 kb) and divergently transcribed.
Typical of housekeeping genes, TBP and PSMB1 express ubiquitously
and contain promoters encompassed by methylation-free CpG islands
(CGI). Functional expression analysis of a 44 kb TBP-PSMB1 fragment
in stably transfected murine ﬁbroblast L-cells after 60 days showed a
level of TBP expression comparable to day zero, suggesting that this
region protected the TBP promoter against silencing and enabled
continuous and stable expression. In an eﬀort to identify the location
of regulatory elements of the TBP-PSMB1 locus, DNase I hypersensitiv-
ity site mapping showed the presence of hypersensitive sites only at the
TBP and PSMB1 promoters (Harland et al., 2002). The authors
concluded that the combination of stable TBP expression within a
transgene context, together with DNase I hypersensitivity sites is
structurally unlike that of previously identiﬁed LCRs (Li et al., 2002;
Tam et al., 2006), indicating that a novel class of regulatory elements,
which acts to negate epigenetic-mediated silencing and remodel
chromatin structure, had been discovered.
Further functional expression analysis of the TBP-PSMB1 locus was
undertaken, together with a second region of similar genomic archi-
tecture, the HNRPA2B1-CBX3 locus (Fig. 1B). The HNRPA2B1-CBX3
locus consists of a region of closely-linked, divergently-transcribed
housekeeping genes: heterologous nuclear ribonucleoprotein A2/B1
(HNRPA2B1) and heterochromatin protein 1Hs-γ (CBX3). A 2.6 kb
methylation-free CGI (deﬁned as such because it has a GC content of
61.5% and an observed-to-expected CpG of ratio of 0.97, meaning that
this region is GC rich and contains a far greater density of CpG
dinucleotides than would be expected by chance, overlies the ﬁrst
alternate exons of CBX3 and the ﬁrst exon of HNRPA2B1 (Antoniou
et al., 2003; Williams et al., 2005). These early functional studies
showed that the TBP-PSMB1 and HNRPA2B1-CBX3 loci, including their
dual divergently transcribed promoter regions, are able to dominantly
open chromatin and confer stable gene expression as demonstrated by
their ability to function even with transgene integration events into
centromeric heterochromatin, with no observed position eﬀect variega-
tion (Antoniou et al., 2003), and thus represent the prototypical UCOEs.
The potential applications of UCOEs were ﬁrst illustrated in 2005.
Investigators linked fragments of the HNRPA2B1-CBX3 methylation-
free CGI and associated promoters (A2UCOE) to the immediate-early
promoter-enhancer region of the human cytomegalovirus (hCMV).
Expression from the HNRPA2B1 and CBX3 promoters is relatively low
and the hCMV promoter region represents a non-selective, strong
promoter-enhancer combination commonly used in mammalian cells
to achieve high level expression of linked genes. It was observed that
the linkage of various sized fragments (1.5 kb, 4 kb, and 8 kb) of the
A2UCOE to the hCMV promoter resulted in a marked elevation of
transgene expression and a resistance to silencing for up to 107–199
generations within stably transfected Chinese Hamster Ovary (CHO) K1
cells (Williams et al., 2005). This ability of the A2UCOE to confer a site
of integration-independent, dominant chromatin-opening function and
to protect linked transgenes from silencing showed great promise for
biomanufacturing and gene therapy.
Structural similarities between the TBP-PSMB1 UCOE and A2UCOE
suggested potential functional mechanisms through common character-
istics (Fig. 1). Both loci consisted of dual divergently-transcribed
housekeeping genes with promoters encompassed by an extensive
methylation-free CGI; it was therefore proposed that the chromatin
remodelling capacity of UCOEs stemmed from the presence and
combination of these features. Characterisation of the epigenetic
signature of the native A2UCOE region in peripheral blood mono-
nuclear cells revealed the coexistence of active histone H3 methylation
and acetylation marks at the transcriptional start sites of HNRPA2B1
and CBX3. Euchromatic histone H4 acetylation was also observed to be
present throughout the A2UCOE region. However, overall histone
modiﬁcations within the proximity of the A2UCOE were sparse due
to nucleosome depletion (Lindahl Allen and Antoniou, 2007; Majocchi
et al., 2014). Reduction of the levels of repressive histone marks
Fig. 1. The genomic organization of the prototypical ubiquitous chromatin opening elements (UCOEs). An overview of the (A) HNRPA2B1-CBX3 A2UCOE, (B) TBP-PSMB1 UCOE, and (C)
Rps3 UCOE regions, showing publicly available epigenomic data. CGI position (green bars with CpG count to their left), GC percentage (black columns each representing 5 bp; 0–100%),
DNase I hypersensitivity sites (grey and black bars; the darkness of the bar reﬂects the assay signal intensity, with a darker bar indicating a stronger signal), and layered H3K27 acetylation
marks from seven cell lines (each colour blue represents a cell line; density 0–100%). (A) The A2UCOE genomic region consisting of the closely-linked and divergently-transcribed ﬁrst
exon and promoter of HNRPA2B1 and the alternate ﬁrst exons and promoters of CBX3. (B) The TBP-PSMB1 locus consisting of the closely-linked and divergently-transcribed ﬁrst exons
and promoters of TBP and PSMB1. (C) The murine Rps3 locus. University of California, Santa Cruz (UCSC) genes track from the UCSC genome browser: http://genome.ucsc.edu/index.
html. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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(H3K9me3 and H3K27me3), extensive areas of unmethylated DNA, and
histone acetylation within the A2UCOE is thought to facilitate expres-
sion at the divergently-transcribed promoters and thus to initiate
euchromatic remodelling (Majocchi et al., 2014). It was also proposed
that a minimal functional region of the A2UCOE CGI was required for
UCOE function (Lindahl Allen and Antoniou, 2007).
However, the discovery of the murine ribosomal protein S3 (Rps3)
UCOE (Fig. 1C) cast doubt on the requirement for dual divergent
transcription for UCOE function. In contrast to the TBP-PSMB1 UCOE
and the A2UCOE, the Rps3 UCOE consists of a single housekeeping gene
promoter element associated with a 358 bp CGI. A 3 kb Rps3 element
linked to the hCMV promoter produced high levels of enhanced green
ﬂuorescent protein (EGFP) expression at day 28, comparable to that of
the HNRPA2B1 promoter (Simpson et al., 2009). Thus the Rps3 UCOE
represents an eﬀective UCOE containing a single housekeeping gene
encompassed by a CGI.
3. Biomanufacturing applications of UCOEs
Modern biomedical research and many biotechnological techniques
rely upon the eﬃcient, cost-eﬀective, robust production of large
quantities of high quality protein in a short period of time. Tissue
culture cell lines adapted to suspension growth in serum free media
provide a scalable and easily puriﬁable source of therapeutic proteins.
CHO cells are currently the most widely used mammalian host for
recombinant protein production due to their well-established safety and
simplicity of use (Jostock and Knopf, 2012; Wurm, 2004).
Benton and colleagues showed as early as 2002 that A2UCOE-
regulated transgenes integrated into CHO sub-clones adapted to grow in
suspension and survive in serum-free media (CHO-S), are able of
rapidly producing large quantities of protein, with the production of
up to 0.2 g/L of recombinant antibody (20 g produced in a 100 L
bioreactor) obtained within ﬁve weeks of transfection (Benton et al.,
2002). The presence of the A2UCOE also aﬀords increased recombinant
protein expression per vector copy number at reproducible levels, with
small variation in expression within and between cell lines transfected
with UCOE-containing vectors, compared to cells transfected with non-
UCOE-containing vectors (Betts and Dickson, 2015).
Many biomanufacturing applications of UCOEs focus on the produc-
tion of monoclonal antibodies (Betts et al., 2015; Betts and Dickson,
2015; Boscolo et al., 2012; Dharshanan et al., 2014; Hou et al., 2014).
By comparing the eﬃciency of recombinant antibody production when
using a 4 kb A2UCOE-based vector against a standard hCMV promoter-
driven expression system in CHO-S cells, it was observed that the use of
the A2UCOE-based vector system resulted in a higher overall level of
expression of antibody relative to the standard hCMV promoter.
Furthermore the A2UCOE-based vector showed a higher number of
stably transfected clones, and outperformed constructs at medium-scale
protein production levels where transgene expression was from the
hCMV promoter alone, with antibody yields of 180–230 mg obtained
per 1 L bioreactor ﬂask (Boscolo et al., 2012). Similarly, upon compar-
ison of an A2UCOE-based system against a commercially available
immunoglobulin expression vector (pFUSE) for stability and expression
levels of heavy and light chains of the humanised anti-C2 monoclonal
antibody, the UCOE-based vector, upon transduction into preadapted
serum-free CHO cells, produced a greater number of stable clones with
recombinant antibody production levels of up to 50–110 mg/L
(Dharshanan et al., 2014).
The period of time from initial transfection up to the identiﬁcation
and culture of a clonal cell population expressing a transgene at high
levels is a rate-limiting step in recombinant antibody production. Hou
and colleagues used the 3 kb Rps3 or the 8 kb A2UCOE linked to either
a guinea pig CMV or hCMV promoter expressing IgG-1 and IgG-4 light
and heavy monoclonal antibody chains to develop a rapid method for
early-stage cell line development and clonal isolation in suspension-
adapted CHO cells. The usage of UCOE-based vectors paired with
robotic clone selection allowed the investigators to move from transfec-
tion to culture of high-expressing clones in only four weeks (Hou et al.,
2014). Similarly, CHO cells stably transfected with UCOE-containing
vectors expressing EGFP and erythropoietin (EPO) showed improved
growth and survival, and retention of stable protein expression under
selection with methotrexate, providing a means to identify and culture
stably transfected cells (Betts et al., 2015; Betts and Dickson, 2015). The
usage of UCOEs also resulted in fewer chromosomal rearrangements
after selection with methotrexate, and greater homogeneity of chromo-
somal site integration over long-term culture compared to non-UCOE-
containing vectors (Betts and Dickson, 2016).
In order to determine the most eﬀective chromatin remodelling
element for the production of monoclonal antibodies, Saunders and
colleagues compared the function of a core 1.5 kb A2UCOE sub-
fragment (Williams et al., 2005) to a series of border-type genetic
regulatory elements, which function to block the spreading of repres-
sive epigenetic marks: the MAR X_S29 S/MAR (Girod et al., 2007), the
STAR40 element (Kwaks et al., 2003), and the chicken β-globin HS4
insulator (Barkess and West, 2012). These four chromatin remodelling
elements were positioned at various locations relative to the heavy and
light chain antibody transcription units driven by hCMV promoters
within a single plasmid vector. Following the stable transfection and
positive selection of CHO pools of cells, the A2UCOE-containing vector
showed improved stability and greater than six-fold increase in anti-
body expression compared to the S/MAR, STAR, and insulator element
containing vectors (Saunders et al., 2015).
Besides early successes in antibody production, UCOEs have shown
eﬃcacy in expressing other recombinant proteins. CHO cells trans-
fected with a vector construct containing an 8 kb A2UCOE linked to a
hCMV-EPO cassette were cultured at high cell density and resulted in
the isolation of greater numbers of highly expressing clones, higher
mean EPO production, and greater mRNA recovery per vector copy
number compared to a non-UCOE containing vector (Betts and Dickson,
2015).
A comparison of the 3 kb Rps3 UCOE and 1.5 kb A2UCOE core sub-
fragment linked to seven diﬀerent heterologous promoters expressing a
large B-domain deleted factor VIII (BDD-FVIII) blood clotting factor
gene, was undertaken in the baby hamster kidney (BHK) ﬁbroblast cell
line (Nair et al., 2011). Linked to all heterologous promoters tested, the
A2UCOE showed greater levels of BDD-FVIII production and activity in
adherent and serum-free suspension cultures. However, in CHO cells,
the Rps3 UCOE linked to hCMV was shown to outperform the A2UCOE,
illustrating the importance of identifying the most eﬀective UCOE-
promoter combination for a given cell line (Simpson et al., 2009). A
recent study systematically compared the eﬀect of diﬀerent factors on
antibody production, including the use of UCOEs and promoters, in
CHO-S cells (Rocha-Pizaña et al., 2017). The authors compared the use
of double (Rps3 and 1.5 kb A2UCOE) and single (Rps3) UCOE-contain-
ing vectors, and found that the double UCOE-based vector gave a higher
level of antibody production. In addition, three diﬀerent heterologous
promoters linked to the Rps3 UCOE were compared for their ability to
drive expression of either the anti-TNFα or anti-CD20+ antibodies. The
results varied, indicating that the most eﬀective promoter is dependent
on the protein being expressed. Furthermore, the order of heavy and
light chain genes in the expression cassette was investigated and found
to have no signiﬁcant eﬀect on antibody production (Rocha-Pizaña
et al., 2017).
Experiments involving co-transfection of plasmid vectors harbour-
ing separate light and heavy chain antibody cassettes under the control
of the hCMV promoter with and without the A2UCOE, have also been
reported (Nematpour et al., 2017). The results obtained indicate that
including the A2UCOE as part of the heavy chain gene cassette is most
crucial to obtaining increased and stable antibody output compared
with constructs not containing the A2UCOE. (Nematpour et al., 2017).
UCOEs are available commercially for biomanufacturing and re-
search applications in the form of ready-to-use plasmid vectors contain-
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ing expression and selection elements and as DNA sequences that can be
cloned into a vector of choice. An illustration of using the commercial
UCOE vector oﬀering is shown in Fig. 2. Here expression of four
diﬀerent monoclonal antibodies were compared in the presence and
absence of the 3 kb Rps3 UCOE in diﬀerent CHO cell-based hosts. For
this purpose, triplicate ﬂasks of cells were stably transfected, placed
under selection in bulk and then analyzed in batch cultures. Although
expression of the individual monoclonal antibodies diﬀered across the
panel, the inclusion of the Rps3 UCOE in the vector improved bulk
stable pool expression by> 10-fold for each antibody (Fig. 2).
The inclusion of the Rps3 UCOE confers beneﬁts in the cell line
development process beyond increased monoclonal antibody titres
(Fig. 2). Bulk Rps3-UCOE and non-UCOE vector-derived cell pools
(Fig.2) were separated into single cell clones by limiting dilution and
expanded in static cultures for two weeks. At that time,> 500 clones
for UCOE and non-UCOE control cultures were evaluated for cell
number and monoclonal antibody titer. Titer was divided by cell
number to provide a relative expression level and the most productive
100 clones for each pool are shown in descending order (Fig. 3).
Strikingly, the speciﬁc productivity of UCOE-derived clones dwarfs the
collective productivity of the control clones. Furthermore, each of the
100 UCOE-derived clones has higher relative productivity than 98% of
the control clones. The most productive 20 clones were selected for
batch culture titer evaluation and the results of the top ﬁve UCOE-
derived and control cultures are shown in the inset of Fig. 3. UCOE-
derived clones produced as much as 0.7 g/L in the small scale batch
evaluation whereas the control cultures produced< 0.1 g/L. Since the
incorporation of the Rps3 UCOE aids in promoting stable transgene
expression, fewer clones need to be screened to isolate high producers
of the desired therapeutic protein. Moreover, the increased productivity
of UCOE-derived clones alleviates the need to amplify the integrated
transgenes as in DHFR CHO based systems (Gu et al., 1992; Kaufman
and Sharp, 1982). Therefore, UCOE-based vectors provide beneﬁts in
the cell line development workﬂow including reduced resources
required as well as potential time savings to isolate highly productive
clones.
In summary, UCOEs confer reproducible and stable high levels of
linked gene expression when stably transfected into serum-free, suspen-
sion-adapted, and adherent cell lines widely used in biomanufacturing
applications. Furthermore, UCOEs have shown utility in the rapid
Fig. 2. UCOE enhances bulk titer monoclonal antibody expression. Four diﬀerent monoclonal antibodies were cloned into MilliporeSigma commercial oﬀering of single expression or dual
plasmid expression vectors with and without the Rps3 UCOE. DNA was stably transfected into suspension-adapted CHO host cells by electroporation and cells selected for transgene
integration by addition of puromycin and then subjected to antibody titer evaluation secreted into the batch culture medium. Titers were obtained using HPLC.
Fig. 3. UCOE enhances the productivity of clonal cells. Bulk pools of stably transfected UCOE vector-derived and control cultures were sub-cloned using limiting dilution. Greater than
500 clones of each were analyzed for antibody titer secreted into the culture medium using an ELISA and analyzed for cell number by ﬂow cytometry. Relative Productivity is represented
as the ratio of monoclonal antibody titer divided by the cell number measurement. The inset shows the batch antibody titer of the ﬁve highest expressing UCOE-derived and non-UCOE
control clones as determined by ELISA.
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selection and isolation of highly expressing clones. The usage of UCOEs
within biomanufacturing holds promise for expediting upstream bio-
manufacturing stages by facilitating the production and selection of a
candidate clonal cell population in less than three months. However,
there is still a requirement to select the most eﬀective UCOE-hetero-
logous (viral) promoter combination for maximum protein therapeutic
biomanufacture depending on the nature of the protein to be produced
and especially the cell line to be employed.
4. Applications of UCOEs in gene therapy
Gene therapy is the treatment of a disease or medical disorder
through the introduction of exogenous therapeutic genetic material into
appropriate cellular targets in order to overcome the eﬀects of speciﬁc
genetic mutations and/or to normalise cellular function. Successful
gene therapy therefore relies upon a means to introduce exogenous
genetic material in an eﬃcient, target-speciﬁc manner, and the stable
incorporation and expression of the genetic material from within the
target cell for the appropriate period of time.
Lentiviral vectors (LVs) represent one of the most promising gene
delivery systems in the ﬁeld of human gene therapy. LVs oﬀer a reliable
means by which exogenous genetic material can be integrated into
dividing and non-dividing target cell genomes and their use has shown
encouraging outcomes in a number of clinical trials for conditions such
as primary immunodeﬁciencies (Sauer et al., 2014) and leukodystro-
phies (Aubourg, 2016). Once integrated into the target cell genome the
therapeutic transgenes are inherited upon mitosis and in principle can
be expressed over long periods. However, natural cellular defence
mechanisms mediate the epigenetic silencing of proviral genetic
material through DNA methylation, histone deacetylation, and chro-
matin condensation, acting to diminish or even reverse therapeutic
eﬀects (Antoniou et al., 2013). It is therefore important, if gene therapy
using LVs is to be eﬀective, that the epigenetic silencing of therapeutic
transgenes be prevented by incorporating protective regulatory ele-
ments.
The ﬁrst studies looking at UCOE function within LVs investigated
the use of a 2.2 kb A2UCOE sub-fragment (Fig. 4A, fragment A)
(Antoniou et al., 2003) linked to reporter genes expressing from the
inherent HNRPA2B1 promoter (Fig. 4B, construct I). In this conﬁgura-
tion the A2UCOE was shown to provide higher expression, greater
stability, and more reproducible levels of expression per vector copy
number than the spleen focus-forming virus (SFFV), hCMV, and
elongation factor-1α (EF1α) promoters within ex vivo haematopoietic
stem cell (HSC) transduction-transplantation experiments in mice
(Zhang et al., 2007). The A2UCOE has also been shown to confer
sustained expression of an EGFP reporter in vivo for 10 months, after the
transplantation of transduced human fetal liver-derived HSCs into
immunocompromised mice, whereas in the same period, expression
from vectors driven by PGK and EF1α promoters showed a 5-fold and
22-fold reduction in expression, respectively (Dighe et al., 2014).
Recently the utility of A2UCOE-based LVs has been further extended
by the demonstration that they can confer stable, long-term expression
following pre-natal delivery to the fetal liver and haematopoietic stem
cells (Kao et al., 2016). Furthermore, post-natal haemophilia B curative
levels of human FIX were produced following low level delivery of an
A2UCOE-FIX LV to the fetal liver (Kao et al., 2016).
The capability of the A2UCOE to resist silencing has been found to
be at least in part due to its ability to resist DNA methylation (Zhang
et al., 2010). In summary, whereas in the short-term, there is no
discernible diﬀerence in the levels of expression driven by promoters
with and without a linked UCOE due to the time taken for transgene
silencing (de Poorter et al., 2007), frequently used promoters from
either viruses (SFFV, CMV) or native genes (EF1α, PGK) are invariably
silenced over a period of weeks or months, resulting in a variegated
expression pattern post-transduction and compromised transgene ex-
pression (Dighe et al., 2014; Zhang et al., 2010).
The potential utility of UCOEs within a gene therapy context was
further extended when it was demonstrated that their linkage to tissue-
speciﬁc heterologous promoters retains promoter tissue speciﬁcity,
which frequently demands tissue-restricted therapeutic gene transcrip-
tion. It has been shown that the 1.5 kb A2UCOE core sub-fragment
(Fig. 4A, fragment B) linked to the muscle-speciﬁc desmin (DES) and
granulocyte-speciﬁc myeloid-related protein-8 (MRP8) promoters
(Fig. 4B, construct II) confers stable and appropriate tissue-speciﬁc
expression (Brendel et al., 2012; Talbot et al., 2010). Furthermore, an
A2UCOE-MRP8-gp91phox LV was shown to be able to completely
rescue the X-linked chronic granulomatous disease phenotype in a
mouse model system following ex vivo transduction-transplantation of
HSCs at low average vector copy number per cell (Brendel et al., 2012).
The generation of induced pluripotent stem cells (iPSCs) from adult
human cells with well-deﬁned reprogramming factors, followed by
genetic modiﬁcation, directed diﬀerentiation, and then transplantation
into patients, holds great promise as a treatment in regenerative
medicine (Karagiannis and Eto, 2016; Takahashi et al., 2007). One
potential limitation of this technique is the epigenetic-mediated silen-
cing of therapeutic transgenes introduced into iPSCs, especially upon
their diﬀerentiation down the desired lineage. Because of this, several
investigators have examined the function of UCOEs in this class of stem
cells. The 1.5 kb A2UCOE linked to heterologous promoters has been
found to consistently confer high and stable gene expression in human
and murine iPSCs and in embryonic stem cells before and after
diﬀerentiation into lineages representative of all three germ layers
(Ackermann et al., 2014; Pfaﬀ et al., 2013).
The inherent limited capacity of viral vectors requires that regula-
tory elements present within the incorporated therapeutic transcription
unit must be minimised to allow for maximisation of transgene
capacity. Hence, over the past decade various sized sub-fragments of
UCOEs, particularly those derived from the A2UCOE, have been built
and tested in order to maximise the size available space for linked
transgenes (Fig. 4A). Initial studies showed that a 2.2 kb A2UCOE
region encompassing both the CBX3 and HNRPA2B1 transcriptional
start sites and the methylation-free CGI and with transgenes driven
directly oﬀ the innate HNRPA2B1 promoter (Antoniou et al., 2003),
maintains stable expression in a LV context both in vitro and in vivo
(Zhang et al., 2007). The preferred A2UCOE sub-fragment that confers
stability of expression when linked to heterologous ubiquitous and
tissue-speciﬁc promoters, was the 1.5 kb core element (Fig. 4A, frag-
ment B), which again extends over the alternative ﬁrst exons of CBX3
and into the ﬁrst intron of HNRPA2B1 (Fig. 4B, construct II) (Brendel
et al., 2012; Zhang et al., 2010). A 1.2 kb sub-fragment of this 1.5 kb
element, which lacks 300 bp from the HNRPA2B1 end, was ﬁrst shown
to possess an equal UCOE capability when linked to the highly
silencing-prone SFFV promoter (Zhang et al., 2010). Uchiyama and
colleagues investigated the function of a 0.6-kb A2UCOE sub-fragment
that encompasses only the HNRPA2B1 promoter and 5′ ﬂanking region,
but no CBX3 sequences (Fig. 4A, fragment D). Linked to EGFP and the
Wiskott-Aldrich syndrome protein gene (WAS) (Fig. 4B, construct IV),
this element showed stable and long-term expression upon Foamy virus
vector transduction into HSCs in vitro and in vivo comparable to the
endogenous WAS promoter (Uchiyama et al., 2012). More recently a
0.7 kb A2UCOE-derived sub-fragment incorporating the alternate ﬁrst
exons and promoter of CBX3 (Fig. 4A, fragment C) was shown to
possess anti-silencing functions comparable to that of the 1.5 kb
A2UCOE in multipotent and pluripotent stem cells when linked to the
SFFV and MRP8 promoters (Müller-Kuller et al., 2015). In addition,
expression from the inherent CBX3 promoter of the 0.7 kb sub-fragment
(Fig. 4B, construct III) was also shown to be stable, albeit at very low
levels (Müller-Kuller et al., 2015).
Severe combined immunodeﬁciency (SCID) is a life-threatening
group of primary immune deﬁciencies caused by a number of genetic
mutations that result in the abnormal development of lymphocytes. The
most common form of SCID, representing 50–60% of cases, is X-linked
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SCID (SCID-X1), which is caused by mutations in the interleukin-2
receptor gene (IL2RG) encoding the common γ-chain cytokine receptor
subunit (Fischer, 2000). In 2007, Zhang and colleagues achieved
eﬃcient full immunogenic reconstitution within a SCID-X1 mouse
model system using an LV-A2UCOE-IL2RG cassette based on expression
directly oﬀ the HNRPA2B1 promoter (Fig. 4B, construct I) and an ex
vivo HSC transduction-transplantation procedure at low vector copy
number per cell, which was superior to that obtained with an SFFV-
IL2RG vector (Zhang et al., 2007).
SCID can also stem from deﬁciencies of RAG2, resulting in the total
absence of T and B cells. In a murine Rag2 knockout model system,
incomplete immunogenic reconstitution was achieved with a LV
construct containing an SFFV promoter driving expression of RAG2.
Although T cell proliferation and antibody responses, and plasma
antibody and T cell receptor levels were restored, subnormal levels of
B cells and double-positive T cells were observed. It was concluded that
the silencing of the SFFV promoter through DNA methylation may have
been responsible for the incomplete phenotype reversal. Replacement
of the SFFV promoter with the 2.2 kb A2UCOE (Fig. 4A, fragment A)
resulted in a greater correction of the phenotype, including B cell
reconstitution to near normal levels (van Til et al., 2012).
Mutant O6-methylguanine DNA methyltransferase (MGMTP140K) is
protective against certain chemotherapeutic agents and has shown
clinical potential as a myeloprotective agent in glioblastoma patients
treated with temozolomide (Adair et al., 2012). Transduction of
myeloid and lymphoid cells with an LV containing an 1.5 kb
A2UCOE-PGK promoterMGMTP140K construct provided high and stable
levels of expression, which allowed for transgenic cell selection and
conferred signiﬁcant myeloprotection against a combination of O6-
benzylguanine and carmustine in a mouse model (Phaltane et al.,
2014).
The risks of insertional mutagenesis are reduced through the usage
of self-inactivating (SIN) viral vector systems. However, enhancer
elements found in internal regulatory regions present within transgenes
can still possess mutagenic potential. The A2UCOE is an enhancer-less
element and as such vectors incorporating the A2UCOE are at reduced
risk of insertional mutagenesis events compared to vectors containing
enhancers (Zhang et al., 2007). A second safety consideration is the
Fig. 4. HNRPA2B1-CBX3 genomic region and functional A2UCOE sub-fragments. (A) Top panel: illustration of the HNRPA2B1-CBX3 promoter and methylation-free CGI region. Rectangles
with associated arrows represent the ﬁrst exons of the two genes and direction of transcription. Lower panel: lines A–D denoting extents and lengths of sub-fragments of the HNRPA2B1-
CBX3 promoter-CGI region showing A2UCOE function. (B) Illustration of lentiviral vectors showing transgenes under control of A2UCOE sub-fragments. Construct I: 2.2 kb A2UCOE
driving expression of a gene of interest (GOI) directly from the innate HNRPA2B1 promoter. Construct II: augmentation of heterologous promoter (grey box) activity by linkage of the
1.5 kb A2UCOE fragment. Note: the 1.5 kb A2UCOE can be replaced with other sub-fragments of this element within this transcription unit design. Construct III: 0.7 kb CBX3 sub-
fragment driving expression from its own promoter. Construct IV: 0.6 kb HNRPA2B1 promoter fragment driving expression from its innate promoter.
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elimination of aberrant splicing. A number of studies have reported
examples of vector-mediated aberrant splicing, a potential source of
vector toxicity (Almarza et al., 2011; Cavazzana-Calvo et al., 2010;
Moiani et al., 2012; Montini et al., 2009). Knight and colleagues
reported that both native and activated cryptic splice donor sites within
the A2UCOE act as sources of aberrant transcripts (Knight et al., 2012).
However, targeted point mutations successfully inactivated splice
donor sites within the A2UCOE, negating this source of potential
insertional mutagenesis (Knight et al., 2012).
In addition to its use within LV systems, the A2UCOE has also been
evaluated in a non-viral replicating episomal plasmid vector context.
Upon incorporation into a plasmid, the 1.5 kb A2UCOE linked upstream
of an hCMV promoter stably increased levels of transgene expression
(Hagedorn et al., 2013).
The functional characteristics of UCOEs are unprecedented amongst
genetic regulatory elements. Compared to other commonly used
promoters, the A2UCOE, with expression from either the innate
HNRPA2B1 promoter or when linked to a heterologous promoter,
shows greater stability and levels of transgene expression. The
A2UCOE also conserves tissue-speciﬁc expression and maintains stabi-
lity of expression in adult, embryonic, and induced pluripotent stem
cells before and after diﬀerentiation. Thus the A2UCOE is potentially a
powerful tool in both LV and episomal plasmid vector gene therapy
contexts.
5. Conclusion
The UCOE class of genetic regulatory elements shows broad and
well-established utility in protein therapeutic biomanufacturing and
encouraging applications in retroviral vector-based gene therapy. In
cell lines commonly used for the production of recombinant mono-
clonal antibodies and other proteins, UCOEs based on the human
HNRPA2B1-CBX3 and murine Rps3 loci have shown the ability to confer
reproducible and high levels of linked gene expression and protein
production. In many instances, expression is higher with the UCOE than
with standard protocols and expression systems. The utility of UCOEs to
markedly expedite the rapid selection of highly-expressing cell clones
has also been shown. As such, the UCOE-based gene expression plat-
form shows promise as a means to improve the time and cost eﬃciency
of upstream biomanufacturing stages by increasing the proportion of
stable highly-expressing clones and expediting clonal cell line isolation.
The A2UCOE has been the mostly widely investigated UCOE in the
ﬁeld of gene therapy. Alone or linked to heterologous ubiquitous or
tissue-speciﬁc promoters, the A2UCOE has been shown to confer stable
and long-term transgene expression not only in somatic cells, but also in
adult, embryonic, and induced pluripotent stem cells, and their
diﬀerentiated progeny. The A2UCOE has been shown to outperform
other commonly used promoter elements over extended time periods,
including the hCMV, SFFV, EF1α, and PGK promoters. The A2UCOE
functions in viral and plasmid vector contexts and functional sub-
fragments of the A2UCOE have been identiﬁed, enabling the maximisa-
tion of vector transgene capacity. Several studies have shown clinical
promise for the A2UCOE as a ubiquitously-acting gene therapy
regulatory element where long-term, high expression levels are re-
quired with minimal variation and insertional mutagenesis risk.
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